Ramosetron
| Evidence Level: L5 | Predicted Indications: 2 |
Table of Contents
Ramosetron: From IBS-D/CINV to Insomnia
One-Sentence Summary
Ramosetron is a selective 5-HT3 receptor antagonist known pharmacologically for use in irritable bowel syndrome with diarrhea (IBS-D) and chemotherapy-induced nausea and vomiting (approved in Japan/Korea; no India regulatory data on file). The TxGNN model predicts it may be effective for Insomnia, but currently no clinical trials and no publications support this direction — the prediction rests on the knowledge graph score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | IBS-D / Chemotherapy-Induced Nausea and Vomiting (based on known 5-HT3 antagonist classification; no India license data available) |
| Predicted New Indication | Insomnia |
| TxGNN Prediction Score | 99.73% |
| Evidence Level | L5 |
| India Market Status | Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, ramosetron is a selective 5-HT3 receptor antagonist, a class primarily used for IBS-D and chemotherapy-induced nausea/vomiting through blockade of serotonin signaling in the gut and central chemoreceptor trigger zone.
The proposed link to insomnia relies on the theoretical involvement of 5-HT3 receptors in central serotonergic transmission, which is broadly connected to sleep-wake regulation. However, this connection is speculative — there is no pharmacological, preclinical, or clinical data specifically tying ramosetron’s mechanism to sleep-wake cycle modulation. The evidence pack itself flags this as a “theoretical inference only,” which is why the evidence level is capped at L5 (model prediction only).
A second candidate, migraine disorder (score 99.06%), was also flagged, drawing on the loose precedent of other 5-HT3 antagonists (e.g., ondansetron) being used off-label for migraine-associated nausea — but again this is symptomatic, not mechanism-targeted, and lacks any ramosetron-specific evidence.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
India Market Information
No registration records are currently available for ramosetron in India (market status: Not Marketed, 0 licenses on file).
Safety Considerations
Please refer to the package insert for safety information.
Note: TFDA-equivalent label warnings/contraindications are flagged as a Blocking data gap (DG001) — this must be resolved before any S1 safety pre-assessment can proceed.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by a TxGNN knowledge-graph score with no corroborating clinical trials, literature, or established mechanistic pathway (evidence level L5). Combined with the absence of India market presence and missing label/safety data, this candidate does not meet the threshold to advance.
To proceed, the following is needed:
- Confirmed mechanism of action (MOA) data from DrugBank or primary literature
- Local label warnings/contraindications (DG001 — currently blocking)
- Preclinical or mechanistic evidence linking 5-HT3 antagonism to sleep-wake regulation
- At minimum, early-phase clinical or observational data before re-scoring above L5
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.